Staying on 1mg Wegovy longer than planned — what the evidence says

What the trial evidence tells us about the 1mg dose and weight loss

The STEP 1 trial (published in the New England Journal of Medicine) followed adults with obesity over 68 weeks. Participants who reached and stayed on the 2.4mg maintenance dose achieved an average body-weight reduction of around 15%. The dose schedule used in that trial was the same one now written into the Wegovy SmPC: a graduated climb through 0.25mg, 0.5mg, 1mg and 1.7mg before reaching 2.4mg. No arm of the trial was designed to assess long-term outcomes at 1mg specifically, which is why prescribers are cautious about treating that dose as a resting point rather than a waypoint.

That context matters. If you want to read more about what happens at this specific stage, our page on Wegovy 1mg explains what to expect from the dose in plain terms, including how it fits into the wider titration journey. Staying there indefinitely means the weight-loss signal from semaglutide is likely to be weaker than it could be, because the medicine's appetite-suppressing effect strengthens with dose. This is not a reason to rush, but it is the clinical logic behind the default schedule.

If you want to understand how dose levels relate to what the medicine can do for you, the overview on our Wegovy dose guide sets out the full schedule in plain terms.

Why some people stay on 1mg Wegovy for longer, and what the guidance says about it

The official patient information and prescribing guidance acknowledge that not everyone can tolerate moving up on the standard four-weekly timetable. Nausea, vomiting and other gastrointestinal effects are the usual reasons someone asks about staying put at 1mg. The NHS medicines page for semaglutide notes that these side effects are common, particularly around dose increases, and often ease as the body adapts, typically within a week or two.

Where they don't ease, or where they're severe enough to affect daily life, a prescriber may recommend holding at the current dose for a further four weeks before trying to progress. This is a managed pause, agreed with a clinician, with a plan attached. It's different from quietly deciding not to collect the next pen in the sequence, which cuts the prescriber out of the picture and can create gaps that complicate re-titration later.

It is also worth knowing that staying on 1mg is not the same as staying on a lower dose by personal preference. There is a separate question about whether remaining at 1mg long-term is ever clinically supported, and the answer is nuanced, some people genuinely cannot tolerate higher doses and their prescriber manages accordingly, but this is the exception rather than the rule.

Practical things to consider while your dose is on hold

If your prescriber has agreed a temporary hold at 1mg, a few practical points are worth bearing in mind. First, keep your injection routine consistent, same day each week, ideally at the same time. Keeping the pen in the fridge door and associating the injection with a regular weekly moment (putting the shopping away, for instance) is the kind of low-friction habit that prevents missed doses during a longer hold period.

Second, the side effects that prompted the hold may return when you eventually step up, since you'll be going through another dose increase. When you are ready to move forward, our guide to your new Wegovy dose covers what to expect as you progress to the next stage, which can help you feel more prepared before you make that change. Third, the broader question of staying on a lower Wegovy dose covers how prescribers think about this across the whole titration journey, it's worth reading alongside this page if you're weighing whether to press on or hold.

Wegovy is a prescription medicine, and any change to the titration schedule should happen in conversation with the clinician who knows your case. If you're not already on treatment and are wondering whether Wegovy could suit you, our free consultation connects you with a GPhC-registered prescriber for a same-day clinical review.

Cost and repeat access while staying at 1mg

One practical side effect of staying at 1mg for longer than expected is that your supply pattern may shift. If your repeat prescription was written expecting a move to 1.7mg, you and your prescriber may need to adjust. This is also a sensible moment to look at the cost of Wegovy by dose, since prices vary between dose levels and a longer period at 1mg changes what you'll spend month to month.

At nume, every repeat order goes through a fresh clinical review before dispatch, there are no auto-renewals that would push the wrong dose out without someone checking. That structure exists precisely for situations like a managed hold: your prescriber is in the loop at every stage, and the repeat is confirmed only once the clinical picture supports it.